Document is current
Any future updates will be listed below
-
Authors
Dannlowski, U
Grabe, H J
Wittfeld, K
Klaus, J
Konrad, C
Grotegerd, D
Redlich, R
Suslow, T
Opel, N
Ohrmann, P
Bauer, J
Zwanzger, P
Laeger, I
Hohoff, C
Arolt, V
Heindel, W
Deppe, M
Domschke, K
Hegenscheid, K
Völzke, H
Stacey, D
Meyer zu Schwabedissen, H
Kugel, H
Baune, B T
- License Information
-
More Information
Article History
Received: 26 September 2013
Revised: 9 February 2014
Accepted: 17 March 2014
First Online: 29 April 2014
Competing interests
: Professor Volker Arolt, MD, PhD is a member of advisory boards and/or gave presentations for the following companies: AstraZeneca, Janssen-Organon, Lilly, Lundbeck, Servier, Pfizer and Wyeth. He also receives funds from the German Ministry of Education and Research (BMBF) and from the European Union (EU-FP7). Professor Bernhard T Baune, MD, PhD, MPH is a member of advisory boards, received funding and/or gave presentations for the following companies: AstraZeneca, Lundbeck, Pfizer, Servier and Wyeth. He receives funding from the National Health and Medical Research Council (NHMRC) Australia. Professsor Katharina Domschke, MA, MD, PhD, received speaker’s honoraria by Pfizer, Lilly and Bristol–Myers Squibb, has been a consultant for Johnson&Johnson, and has received funding by AstraZeneca. Professor Hans J Grabe received speakers honoraria by Lilly and Servier. Professsor Peter Zwanzger has received speaker fees from Pfizer, Servier, Lilly, AstraZeneca and Bristol–Myers Squibb, is on the advisory board of Pfizer, is a consultant for Ironwood Pharmaceuticals, and has received funding from AstraZeneca. All other authors declare no conflict of interest.
